Hemostemix Inc. (HMTXF)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.5 Million CAD | 52.21% |
| 2022 | -5.23 Million CAD | 16.71% |
| 2021 | -6.28 Million CAD | 19.09% |
| 2020 | -7.76 Million CAD | -59.52% |
| 2019 | -4.86 Million CAD | 21.3% |
| 2018 | -6.18 Million CAD | -57.25% |
| 2017 | -3.93 Million CAD | -3.97% |
| 2016 | -3.78 Million CAD | 5.03% |
| 2015 | -3.98 Million CAD | 8.02% |
| 2014 | -4.33 Million CAD | -181.24% |
| 2013 | -1.54 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -519.34 Thousand CAD | -9.21% |
| 2024 Q1 | -475.53 Thousand CAD | 30.44% |
| 2023 Q4 | -683.58 Thousand CAD | -165.74% |
| 2023 FY | -2.5 Million CAD | 52.21% |
| 2023 Q1 | -1.27 Million CAD | 5.27% |
| 2023 Q2 | -284.94 Thousand CAD | 77.68% |
| 2023 Q3 | -257.24 Thousand CAD | 9.72% |
| 2022 Q4 | -1.34 Million CAD | -66.24% |
| 2022 Q2 | -1.44 Million CAD | 11.59% |
| 2022 Q1 | -1.63 Million CAD | 49.14% |
| 2022 FY | -5.23 Million CAD | 16.71% |
| 2022 Q3 | -810.52 Thousand CAD | 43.94% |
| 2021 Q4 | -3.21 Million CAD | -207.76% |
| 2021 Q2 | -1.34 Million CAD | -96.23% |
| 2021 Q3 | -1.04 Million CAD | 22.12% |
| 2021 FY | -6.28 Million CAD | 19.09% |
| 2021 Q1 | -683.7 Thousand CAD | 82.86% |
| 2020 Q4 | -3.98 Million CAD | -147.25% |
| 2020 FY | -7.76 Million CAD | -59.52% |
| 2020 Q3 | -1.61 Million CAD | 20.33% |
| 2020 Q2 | -2.02 Million CAD | -1344.58% |
| 2020 Q1 | -140.2 Thousand CAD | 77.07% |
| 2019 Q4 | -611.45 Thousand CAD | 55.11% |
| 2019 FY | -4.86 Million CAD | 21.3% |
| 2019 Q1 | -1.56 Million CAD | 9.73% |
| 2019 Q2 | -1.32 Million CAD | 15.51% |
| 2019 Q3 | -1.36 Million CAD | -2.69% |
| 2018 Q2 | -1.65 Million CAD | -53.1% |
| 2018 Q1 | -1.08 Million CAD | -17.65% |
| 2018 FY | -6.18 Million CAD | -57.25% |
| 2018 Q4 | -1.73 Million CAD | -1.96% |
| 2018 Q3 | -1.7 Million CAD | -2.79% |
| 2017 FY | -3.93 Million CAD | -3.97% |
| 2017 Q1 | -548.75 Thousand CAD | 36.05% |
| 2017 Q4 | -921.2 Thousand CAD | 62.63% |
| 2017 Q2 | -509.8 Thousand CAD | 7.1% |
| 2017 Q3 | -2.46 Million CAD | -383.51% |
| 2016 Q4 | -858.16 Thousand CAD | 46.46% |
| 2016 FY | -3.78 Million CAD | 5.03% |
| 2016 Q3 | -1.6 Million CAD | -151.73% |
| 2016 Q2 | -636.76 Thousand CAD | 7.26% |
| 2016 Q1 | -686.63 Thousand CAD | 40.98% |
| 2015 Q1 | -888.88 Thousand CAD | 58.0% |
| 2015 FY | -3.98 Million CAD | 8.02% |
| 2015 Q4 | -1.16 Million CAD | -19.27% |
| 2015 Q3 | -975.44 Thousand CAD | -1.89% |
| 2015 Q2 | -957.37 Thousand CAD | -7.71% |
| 2014 FY | -4.33 Million CAD | -181.24% |
| 2014 Q4 | -2.11 Million CAD | -138.27% |
| 2014 Q3 | -888.2 Thousand CAD | -2316.02% |
| 2014 Q2 | -36.76 Thousand CAD | -303.68% |
| 2014 Q1 | -9107.00 CAD | 41.46% |
| 2013 Q2 | -34.73 Thousand CAD | 32.65% |
| 2013 FY | -1.54 Million CAD | 0.0% |
| 2013 Q3 | -16.31 Thousand CAD | 53.03% |
| 2013 Q4 | -15.55 Thousand CAD | 4.65% |
| 2013 Q1 | -51.57 Thousand CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 52.97 Million USD | 104.723% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 64.168% |
| CSL Limited | 2.64 Billion USD | 100.095% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 103.842% |
| Regen BioPharma, Inc. | 1.02 Million USD | 344.464% |
| BioStem Technologies, Inc. | -8.48 Million USD | 70.504% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 34.483% |
| Qrons Inc. | -789.34 Thousand USD | -216.985% |
| Nascent Biotech, Inc. | -2.08 Million USD | -19.851% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 96.003% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 68.34% |
| Skye Bioscience, Inc. | -37.64 Million USD | 93.353% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -502.223% |
| Rebus Holdings, Inc. | -1.02 Million USD | -145.305% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 84.235% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -87.363% |
| Genscript Biotech Corporation | -95.47 Million USD | 97.379% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -295.649% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 96.662% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 61.952% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -815.176% |
| SQZ Biotechnologies Company | -79.46 Million USD | 96.851% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 13.493% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -37.439% |
| Mesoblast Limited | -87.95 Million USD | 97.155% |
| Marizyme, Inc. | -65.34 Million USD | 96.171% |
| Genus plc | 7.9 Million USD | 131.672% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 77.027% |
| Pharming Group N.V. | -10.54 Million USD | 76.279% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -15.314% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 32.562% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 71.708% |
| ContraFect Corporation | -65.15 Million USD | 96.16% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 48.791% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -44.844% |
| IMV Inc. | -36.48 Million USD | 93.142% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 68.955% |
| MultiCell Technologies, Inc. | -380.07 USD | -658228.466% |
| ONE Bio Corp. | 8.67 Million USD | 128.837% |
| Accustem Sciences Inc. | -3.74 Million USD | 33.213% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 95.16% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -97.462% |
| Q BioMed Inc. | -2.05 Million USD | -21.93% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 32.973% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -5.092% |
| Biomind Labs Inc. | -1.21 Million USD | -106.05% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 95.811% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 19.333% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -28.363% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -16607.459% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 56.988% |
| GB Sciences, Inc. | -1.36 Million USD | -83.752% |
| Alpha Cognition Inc. | -13.77 Million USD | 81.833% |
| HST Global, Inc. | -146.21 Thousand USD | -1611.312% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -42.589% |
| Halberd Corporation | -79.67 Thousand USD | -3040.355% |
| Enzolytics Inc. | -2.17 Million USD | -14.943% |
| Agentix Corp. | -1.37 Million USD | -82.076% |
| Resverlogix Corp. | -3.61 Million USD | 30.69% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 21.105% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.152% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 2653.172% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 136.134% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 37.022% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 17.317% |
| AVAX Technologies, Inc. | -6.41 Million USD | 60.988% |
| Zenith Capital Corp. | -10.59 Million USD | 76.386% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -10665.463% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 39.649% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -4039.781% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -24.786% |
| Kadimastem Ltd | -3.3 Million USD | 24.348% |
| Helix BioMedix, Inc. | -1.05 Million USD | -136.929% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -466.897% |
| LadRx Corporation | 400.44 Thousand USD | 724.835% |
| Cell Source, Inc. | -5.32 Million USD | 52.979% |
| Regen BioPharma, Inc. | 1.02 Million USD | 344.464% |
| NovAccess Global Inc. | -4.76 Million USD | 47.536% |
| Affymax, Inc. | -14.42 Million USD | 82.653% |
| Itoco Inc. | -1.86 Million USD | -33.875% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 43.678% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -49.917% |
| Mobile Lads Corp. | -2.26 Million USD | -10.552% |
| CytoDyn Inc. | -49.84 Million USD | 94.98% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -3065.904% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -996.805% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -165.75% |
| SYBLEU INC | -180.3 Thousand USD | -1287.717% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -55.147% |
| International Stem Cell Corporation | -131 Thousand USD | -1810.007% |
| Bioxytran, Inc. | -4.28 Million USD | 41.54% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -4510.313% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 1.112% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 94.795% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -18.359% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -220.419% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 21.019% |
| Neutra Corp. | -233.46 Thousand USD | -971.728% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 87.669% |
| PureTech Health plc | -65.69 Million USD | 96.191% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 88.235% |
| IXICO plc | -1.17 Million USD | -112.403% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 74.795% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 95.62% |
| CSL Limited | 2.64 Billion USD | 100.095% |
| Cellectis S.A. | -103.17 Million USD | 97.575% |